Subscribe

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive:

Completed Research: PRACTICE MANAGEMENT RESEARCH
Abstract #CR06

Impact of PGY2 Oncology Pharmacy Residents’ Learning Experiences During the COVID-19 Pandemic

JHOP - March 2022 Vol 12 Special Feature - HOPA Abstracts

Presenter: Yun Man, PharmD, BCOP, Medication Use Quality and Policy Specialist, Dana-Farber Cancer Institute, Boston, MA

Co-Authors: Megan Menon, PharmD, BCOP, Medication Safety Officer, Pharmacy, Roswell Park Comprehensive Cancer Center, Buffalo, NY; Lijian Cai, PharmD, Chief Pharmacy Officer, Pharmacy, Roswell Park Comprehensive Cancer Center, Buffalo, NY

BACKGROUND: The COVID-19 pandemic caused an unprecedented challenge with supply and demand of staff disruption in the healthcare system.1 The pharmacy residency learning experiences were ultimately affected by the COVID-19 pandemic.2

OBJECTIVE: To evaluate the impact of oncology pharmacy residents’ learning experiences during the COVID-19 pandemic by conducting an inquiry with response measurement from the American Society for Health-System Pharmacists (ASHP)-accredited postgraduate year 2 (PGY2) oncology pharmacy residency programs at National Comprehensive Cancer Network (NCCN) member institutions.

METHODS: We surveyed a stratified sample of ASHP-accredited PGY2 oncology pharmacy residencies at 28 NCCN member institutions through the NCCN Pharmacy Directors Forum. The survey included 43 questions and was delivered to the panel participants. The survey was deployed using the web-based survey tool SurveyMonkey, and targeted oncology pharmacy directors who are involved in PGY2 residency training. The representative of each program had the opportunity to complete the survey or to forward it to an alternative delegate within the program, for completion. Requests to participate were sent through e-mail to the participants. The survey included questions related to the oncology learning experience, pharmacy staffing, educational activities, and onboarding process after the emergence of the COVID-19 pandemic in the United States.

RESULTS: Of the selected 28 residencies that were sent the survey, 17 residencies completed the survey between February 22 and March 19, 2021, resulting in a 60.7% survey response rate. Participating programs mostly have 2 oncology residents and at least 21 oncology pharmacy preceptors. At the time of the survey, 94% of the respondents reported they had no changes in the numbers and duration of the core and elective learning experiences. In all, 82% of the responding programs continued to have residents on the same staffing hours as before the pandemic. As reported by the survey respondents, the activities that were fully transitioned to virtual reporting included educational responsibility (41%), residents–students teaching encounters (11.76%), and conference presentations (87.5%).

CONCLUSION: The oncology pharmacy residency training experience has been affected by the COVID-19 pandemic, with the most significant change reported in shifting the learning experience to a remote format. Flexibility and adaptability are essential for residency programs that are required to undergo rapid structural changes and maintain consistent training experiences for residents.

  1. Welles Sasser C, Wolcott MD, Morbitzer KA, Eckel SF. Lessons learned from pharmacy learner and educator experiences during early stages of COVID-19 pandemic. Am J Health Syst Pharm. 2021;78:872-878.
  2. Moore WJ, Webb A, Morrisette T, et al. Impact of COVID-19 pandemic on training of pharmacy residents and fellows: results from a national survey of postgraduate pharmacy trainees. Am J Health Syst Pharm. 2021;78:1104-1111.
Related Items
HOP(A) Springs Eternal
Bryna Delman Ewachiw, PharmD, BCOP, Mark L. Zangardi, PharmD, BCOP
JHOP - March 2022 Vol 12 Special Feature published on March 22, 2022 in Editorial, HOPA Abstracts
A Pooled Safety Analysis of Loncastuximab Tesirine in Relapsed or Refractory DLBCL in the LOTIS Clinical Trial Program: Incidence, Onset, and Management of Myelosuppression
JHOP - March 2022 Vol 12 Special Feature published on March 22, 2022 in HOPA Abstracts, Lymphoma
Evaluation of Empiric Double Coverage with Tobramycin for Adult Patients with Febrile Neutropenia
JHOP - March 2022 Vol 12 Special Feature published on March 22, 2022 in HOPA Abstracts
Treatment Patterns, Real-World Outcomes, and Resource Use in Patients with Non–MSI-High or Mismatch Repair Proficient Advanced Endometrial Cancer
JHOP - March 2022 Vol 12 Special Feature published on March 22, 2022 in HOPA Abstracts, Gynecologic Cancers
Development and Implementation of a Pharmacist-Led Virtual Clinic Improve the Management of Patients with Metastatic Breast Cancer Receiving CDK4/6 Inhibitors
JHOP - March 2022 Vol 12 Special Feature published on March 22, 2022 in HOPA Abstracts, Breast Cancer
Impact of a Remote Oncology Clinical Pharmacist Program in 4 Community Oncology Practices
JHOP - March 2022 Vol 12 Special Feature published on March 22, 2022 in HOPA Abstracts
Integrated Health-System Specialty Pharmacy Support in Reducing Financial Toxicity of Oral Oncolytic Therapy
JHOP - March 2022 Vol 12 Special Feature published on March 22, 2022 in HOPA Abstracts
Perceptions of PGY2 Oncology Programs on Financial Toxicity Education and Preparedness
JHOP - March 2022 Vol 12 Special Feature published on March 22, 2022 in HOPA Abstracts
Pharmacist-Led Oral Chemotherapy Monitoring Pilot Study and Assessment of Patient-Reported Outcomes and Adherence
JHOP - March 2022 Vol 12 Special Feature published on March 22, 2022 in HOPA Abstracts, Chemotherapy
The Impact of a Comprehensive Immunotherapy Continuing Education Curriculum on Pharmacists’ Knowledge, Competence, and Confidence
JHOP - March 2022 Vol 12 Special Feature published on March 22, 2022 in HOPA Abstracts, Immunotherapy
Copyright © Green Hill Healthcare Communications, LLC. All rights reserved.